Resveratrol: Distribution, properties and perspectives;Resveratrol: Distribución, propiedades y perspectivas

Revista Espanola de Geriatria y Gerontologia

Volumn 48, Issue 2, 2013, Pages 79-88

  Gambini, Juan ^a   López Grueso, Raúl ^b   Olaso González, Gloria ^a   Inglés, Marta ^c   Abdelazid, Khira ^a   El Alami, Marya ^a   Bonet Costa, Vicent ^a   Borrás, Consuelo ^a   Viña, José ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bioavailability; Polyphenols; Resveratrol; Stilbene

Indexed keywords

PHYTOALEXIN; PLANT EXTRACT; RESVERATROL;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LONGEVITY; SHORT SURVEY; TRADITIONAL MEDICINE;

EID: 84875516736     PISSN: 0211139X     EISSN: 15781747     Source Type: Journal    
DOI: 10.1016/j.regg.2012.04.007     Document Type: Short Survey

References (104)

1. Takaoka M.J. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes.fil.). J Fac Sci Hokkaido Imp Univ 1940, 3:1-16.
2. Paul B.M., Deopujari I., Charpentier C. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J Ethnopharmacol 1999, 68:71-76.
3. Trela B.C., Waterhouse A.L. Resveratrol: isomeric molar absorptivities and stability. J Agricultural Food Chem 1996, 44:1253-1257.
4. Aggarwal B.B., Takada Y., Oommen O.V. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 2004, 13:1327-1338.
5. Jeandet P., Douillet-Breuil A.C., Bessis R., Debord S., Sbaghi M., Adrian M. Phytoalexins from the Vitaceae: biosynthesis, phytoalexin gene expression in transgenic plants, antifungal activity, and metabolism. J Agric Food Chem 2002, 50:2731-2741.
6. Wiese W., Vornam B., Krause E., Kindl H. Structural organization and differential expression of three stilbene synthase genes located on a 13kb grapevine DNA fragment. Plant Mol Biol 1994, 26:667-677.
7. Preisig-Muller R., Schwekendiek A., Brehm I., Reif H.J., Kindl H. Characterization of a pine multigene family containing elicitor-responsive stilbene synthase genes. Plant Mol Biol 1999, 39:221-229.
8. Brehm I., Preisig-Muller R., Kindl H. Grapevine protoplasts as a transient expression system for comparison of stilbene synthase genes containing cGMP-responsive promoter elements. Z Naturforsch C 1999, 54:220-229.
9. Langcake P., Pryce R.J. A new class of phytoalexins from grapevines. Experientia 1977, 33:151-152.
10. Langcake P., Pryce R.J. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 1976, 9:77.
11. Calderón A.A., Pedreno M.A., Ros-Barceló A., Muñoz R. Zymographic screening of plant peroxidase isoenzymes oxidizing 4-hydroxystilbenes. Electrophoresis 1990, 11:507-508.
12. Morales M., Alcántara J., Ros Barceló A. Oxidation of trans-resveratrol by a hypodermal peroxidase isoenzyme from Gamay rouge Grape (Vitis vinifera) Berries. Am J Enol Vitic 1997, 48:33-38.
13. Maier-Salamon A., Bohmdorfer M., Thalhammer T., Szekeres T., Jaeger W. Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog. Drug Metab Pharmacokinet 2011, 26:364-373.
14. Soleas G.J., Diamandis E.P., Goldberg D.M. Resveratrol: a molecule whose time has come? And gone?. Clin Biochem 1997, 30:91-113.
15. Sato M., Maulik G., Bagchi D., Das D.K. Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic Res 2000, 32:135-144.
16. Elíes-Gómez J. Efectos de los isómeros del resveratrol sobre la homeostasis del calcio y del óxido nítrico en células vasculares. Santiago de Compostela: Santiago de Compostela Universidade. Servizio de Publicacións e Intercambio Científico; 2009.
17. Siemann E.H., Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 1992, 43:49-52.
18. Soleas G.J., Diamandis E.P., Goldberg D.M. Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 1997, 11:287-313.
19. Palomino O., Gómez-Serranillos M.P., Slowing K., Carretero E., Villar A. Study of polyphenols in grape berries by reversed-phase high-performance liquid chromatography. J Chromatogr A 2000, 870:449-451.
20. Burns J., Yokota T., Ashihara H., Lean M.E., Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002, 50:3337-3340.
21. Hathway D.E., Seakins J.W. Hydroxystilbenes of Eucalyptus wandoo. Biochem J 1959, 72:369-374.
22. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995, 235:207-219.
23. Ferrero M.E., Bertelli A.A., Pellegatta F., Fulgenzi A., Corsi M.M., Bertelli A. Phytoalexin resveratrol (3-4'-5-trihydroxystilbene) modulates granulocyte and monocyte endothelial adhesion. Transplant Proc 1998, 30:4191-4193.
24. Ferrero M.E., Bertelli A.E., Fulgenzi A., Pellegatta F., Corsi M.M., Bonfrate M., et al. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 1998, 68:1208-1214.
25. Nonomura S., Kanagawa H., Makimoto A. Chemical constituents of Polygonaceous plants. I. Studies on the components of Ko-J O-Kon. (Polygonum Cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi 1963, 83:988-990.
26. Hillis W.E., Hart J.H., Yakazi Y. Polyphenols of Eucalyptus sideroxylon wood. Phytochemistry 1974, 13:5.
27. Rolfs C.H., Kindl H. Stilbene synthase and chalcone synthase: two different constitutive enzymes in cultured cells of Picea Excelsa. Plant Physiol 1984, 75:489-492.
28. Anjaneyulu A.S.R., Raghava Reddy A.V., Reddy D.S.K., Ward R.S., Adhikesavalu D., Cameron T.S. Pacharin: a new dibenzo (2,3-6,7) oxepin derivative from bauhinia racemosa lamk. Tetrahedron 1984, 40:4245-4252.
29. Hanawa F., Tahara S., Mizutani J. Antifungal stress compounds from Veratrum grandiflorum leaves treated with cupric chloride. Phytochemistry 1992, 31:3.
30. Chung M.I., Teng C.M., Cheng K.L., Ko F.N., Lin C.N. An antiplatelet principle of Veratrum formosanum. Planta Med 1992, 58:274-276.
31. Kumar R.J., Jyostna D., Krupadanam G.L., Srimannarayana G. Phenanthrene and stilbenes from Pterolobium hexapetallum. Phytochemistry 1988, 27:2.
32. Adrian M.J.P., Veneau J., Weston L.A., Bessis R. Biological activity of resveratrol, a stilbenic compound from grapevines, against Botrytis cinerea, the causal agent for gray mold. J Chem Ecol 1997, 23:1689.
33. Sbaghi M.J., Jeandet P., Faivre P., Bessis R., Fournioux J.C. Development of methods using phytoalexin (resveratrol) assessment as a selection criterion to screen grapevine in vitro cultures for resistance to grey mould (Botrytis cinerea). Euphytica 1995, 86:41-47.
34. Bavaresco L., Fregoni C., Cantu E., Trevisan M. Stilbene compounds: from the grapevine to wine. Drugs Exp Clin Res 1999, 25:57-63.
35. Cassidy A., Faughnan M. Phyto-oestrogens through the life cycle. Proc Nutr Soc 2000, 59:489-496.
36. Miura Y., Chiba T., Miura S., Tomita I., Umegaki K., Ikeda M., et al. Green tea polyphenols (flavan 3-ols) prevent oxidative modification of low density lipoproteins: an ex vivo study in humans. J Nutr Biochem 2000, 11:216-222.
37. Pezet R., Pont V. Methanethiol: a morphogenetic factor produced from L-methionine by Phomopsis viticola Sacc. Can J Microbiol 1980, 26:356-362.
38. Laza-Knoerr A.L., Gref R., Couvreur P. Cyclodextrins for drug delivery. J Drug Target 2010, 18:645-656.
39. Colin D., Gimazane A., Lizard G., Izard J.C., Solary E., Latruffe N., et al. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5-fluoro-uracil sensitivity in human derived colon cancer cells. Int J Cancer 2009, 124:2780-2788.
40. Marel A.K., Lizard G., Izard J.C., Latruffe N., Delmas D. Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells. Mol Nutr Food Res 2008, 52:538-548.
41. Chen X., He H., Wang G., Yang B., Ren W., Ma L., et al. Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. Biomed Chromatogr 2007, 21:257-265.
42. Camont L., Cottart C.H., Rhayem Y., Nivet-Antoine V., Djelidi R., Collin F., et al. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal Chim Acta 2009, 634:121-128.
43. Blache D., Rustan I., Durand P., Lesgards G., Loreau N. Gas chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro incubations. J Chromatogr B Biomed Sci Appl 1997, 702:103-110.
44. Basly J.P., Marre-Fournier F., Le Bail J.C., Habrioux G., Chulia A.J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 2000, 66:769-777.
45. Urpi-Sarda M., Zamora-Ros R., Lamuela-Raventos R., Nivet-Antoine V., Djelidi R., Collin F., et al. HPLC-tandem mass spectrometric method to characterize resveratrol metabolism in humans. Clin Chem 2007, 53:292-299.
46. Zamora-Ros R., Urpi-Sarda M., Lamuela-Raventos R.M., Estruch R., Vazquez-Agell M., Serrano-Martinez M., et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 2006, 52:1373-1380.
47. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem 2006, 13:87-98.
48. 2+ handling in A7r5 vascular myocytes. Eur J Pharmacol 2007, 577:91-99.
49. Yanez M., Fraiz N., Cano E., Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun 2006, 344:688-695.
50. Sang S., Yang I., Buckley B., Ho C.T., Yang C.S. Autoxidative quinone formation in vitro and metabolite formation in vivo from tea polyphenol (-)-epigallocatechin-3-gallate: studied by real-time mass spectrometry combined with tandem mass ion mapping. Free Radic Biol Med 2007, 43:362-371.
51. Klaus V., Hartmann T., Gambini J., Graf P., Stahl W., Hartwig A., et al. 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch Biochem Biophys 2010, 496:93-100.
52. Hadi S.M., Ullah M.F., Azmi A.S., Ahmad A., Shamim U., Zubair H., et al. Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer. Pharm Res 2010, 27:979-988.
53. Delmas D., Aires V., Limagne E., Dutartre P., Mazue F., Ghiringhelli F., et al. Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci 2011, 1215:48-59.
54. Urpi-Sarda M., Jauregui O., Lamuela-Raventos R.M., Jaeger W., Miksits M., Covas M.I., et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005, 77:3149-3155.
55. Jannin B., Menzel M., Berlot J.P., Delmas D., Lancon A., Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004, 68:1113-1118.
56. Casper R.F., Quesne M., Rogers I.M., Shirota T., Jolivet A., Milgrom E., et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 1999, 56:784-790.
57. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141:3657-3667.
58. Abou-Zeid L.A., El-Mowafy A.M. Differential recognition of resveratrol isomers by the human estrogen receptor-alpha: molecular dynamics evidence for stereoselective ligand binding. Chirality 2004, 16:190-195.
59. Crozier A., Jaganath I.B., Clifford M.N. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009, 26:1001-1043.
60. Lancon A., Delmas D., Osman H., Thenot J.P., Jannin B., Latruffe N. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 2004, 316:1132-1137.
61. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
62. Cottart C.H., Nivet-Antoine V., Laguillier-Morizot C., Beaudeux J.L. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010, 54:7-16.
63. Boocock D.J., Patel K.R., Faust G.E., Normolle D.P., Marczylo T.H., Crowell J.A., et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 848:182-187.
64. Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005, 49:472-481.
65. Vitrac X., Desmouliere A., Brouillaud B., Krisa S., Deffieux G., Barthe N. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 2003, 72:2219-2233.
66. Marier J.F., Vachon P., Gritsas A., Zhang J., Moreau J.P., Ducharme M.P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002, 302:369-373.
67. Vitaglione P., Sforza S., Galaverna G., Ghidini C., Caporaso N., Vescovi P.P., et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005, 49:495-504.
68. Bravo L., Abia R., Saura-Calixto F. Polyphenols as dietary fiber associated compounds. Comparative-study on in vivo and in vitro properties. J Agric Food Chem 1994, 42:1481-1487.
69. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003, 36:79-87.
70. la Porte C., Voduc N., Zhang G., Seguin I., Tardiff D., Singhal N., et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010, 49:449-454.
71. Almeida L., Vaz da Silva M., Falcao A., Soares E., Costa R., Loureiro A.I., et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009, 53(Suppl. 1):S7-S15.
72. Tessitore L., Davit A., Sarotto I., Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000, 21:1619-1622.
73. Li Z.G., Hong T., Shimada Y., Komoto I., Kawabe A., Ding Y., et al. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 2002, 23:1531-1536.
74. Banerjee S., Bueso-Ramos C., Aggarwal B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002, 62:4945-4954.
75. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011, 1215:9-15.
76. Yilmaz Y., Toledo R.T. Health aspects of functional grape seed constituents. Trends in Food Sci & Technol 2004, 15:422-433.
77. Sun A.Y., Simonyl A., Wang Q.Y.S. Beyond the French paradox: Protection of grape polyphenols against neurodegenerative processes. Alcoholism-Clin & Experim Research 2004, 28:55.
78. Ashby J., Tinwell H., Pennie W., Brooks A.N., Lefevre P.A., Beresford N., et al. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J Appl Toxicol 1999, 19:39-45.
79. Kopp P. Resveratrol a phytoestrogen found in red wine. A possible explanation for the conundrum of the " French paradox" ?. Eur J Endocrinol 1998, 138:619-620.
80. Turner R.T., Evans G.L., Zhang M., Maran A., Sibonga J.D. Is resveratrol an estrogen agonist in growing rats?. Endocrinology 1999, 140:50-54.
81. Gehm B.D., McAndrews J.M., Chien P.Y., Jameson J.L. Resveratrol a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997, 94:14138-14143.
82. Borrás C., Gambini J., Gómez-Cabrera M.C., Sastre J., Pallardo F.V., Mann G.E., et al. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NFkappaB cascade. Aging Cell 2005, 4:113-118.
83. Borrás C., Gambini J., Gómez-Cabrera M.C., Sastre J., Pallardo F.V., Mann G.E., et al. Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NFkappaB. Faseb J 2006, 20:2136-2138.
84. Hsieh T.C., Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999, 249:109-115.
85. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
86. Dobrydneva Y., Williams R.L., Blackmore P.F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br J Pharmacol 1999, 128:149-157.
87. Lasa A., Schweiger M., Kotzbeck P., Churruca I., Simon E., Zechner R., et al. Resveratrol regulates lipolysis via adipose triglyceride lipase. J Nutr Biochem 2011.
88. Cheong H., Ryu S.Y., Kim K.M. Anti-allergic action of resveratrol and related hydroxystilbenes. Planta Med 1999, 65:266-268.
89. Zini R., Morin C., Bertelli A., Bertelli A.A., Tillement J.P. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 1999, 25:87-97.
90. Pozo-Guisado E., Merino J.M., Mulero-Navarro S., Lorenzo-Benayas M.J., Centeno F., Alvarez-Barrientos A., et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005, 115:74-84.
91. Aziz M.H., Reagan-Shaw S., Wu J., Longley B.J., Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?. FASEB J 2005, 19:1193-1195.
92. Tseng P.C., Hou S.M., Chen R.J., Peng H.W., Hsieh C.F., Kuo M.L., et al. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2011, 26:2552-2563.
93. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
94. Gescher A.J., Steward W.P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 2003, 12:953-957.
95. Turner R.T., Evans G.L., Zhang M., Maran A., Sibonga J.D. Is Resveratrol an estrogen agonist in growing rats?. Endocrinology 1999, 140:50-54.
96. Chen K.H., Cheng M.L., Jing Y.H., Chiu D.T., Shiao M.S., Chen J.K. Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2011, 301:E853-E863.
97. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002, 958:439-447.
98. Agarwal B., Baur J.A. Resveratrol and life extension. Ann N Y Acad Sci 2011, 1215:138-143.
99. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
100. Timmers S., Konings E., Bilet L., Houtkooper R.H., Van de Weijer T., Goossens G.H., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14:612-622.
101. Foti Cuzzola V., Ciurleo R., Giacoppo S., Marino S., Bramanti P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. CNS Neurol Disord Drug Targets 2011, 10:849-862.
102. Tajes M., Gutiérrez-Cuesta J., Folch J., Ortuno-Sahagun D., Verdaguer E., Jimenez A., et al. Neuroprotective role of intermittent fasting in senescence-accelerated mice P8 (SAMP8). Exp Gerontol 2010, 45:702-710.
103. Ortuno J.E., Kontaxakis G., Rubio J.L., Guerra P., Santos A. Efficient methodologies for system matrix modelling in iterative image reconstruction for rotating high-resolution PET. Phys Med Biol 2010, 55:1833-1861.
104. Waterhouse A.L., Lamuela-Raventós R.M. The occurrence of piceid, a stilbene glucoside, in grape berries. Phytochem 1994, 37:571-573.